Prostate Cancer

Study to define maximum tolerated dose of INSM-18 in prostate cancer patients

Published in Cancer Weekly, November 16th, 2004

Insmed Incorporated (INSM) reported that the company will begin clinical development of a small molecule tyrosine kinase inhibitor in collaboration with the University of California, San Francisco School of Medicine, an NCI designated Comprehensive Cancer Center.

Insmed and UCSF will initiate a dose-escalating clinical study primarily designed to define the maximum tolerated dose of INSM-18 in patients with relapsed prostate cancer.

The study will consist of a 28-day extension at each dose level to investigate the effect of INSM-18 on prostate specific antigen (PSA) levels. PSA is a standard serum marker for prostate cancer progression.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-11-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry